Meanwhile, KRASG12D promotes the hexosamine pathway (HBP) to increase the level of protein glycosylation, and KRASG12D maintains pancreatic cancer by activating MAPK and Myc signaling pathways to upregulate glycolysis-related genes (GLUT1, HK1, ENO1, and LDHA), HBP-related genes (GFPT1), and PPP non-oxidative branch genes (RIA), respectively (Ying et al., 2012). The gene discussed is SLC2A1; the disease is pancreatic neoplasm.